GlassScriptPhysician profile
James E Fayssoux
NPI 1407808926
$2,650.76
in general payments reported to CMS, 2019-2025
33 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $161 · 2021: $139 · 2022: $197 · 2023: $514 · 2024: $499 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $396.40 | 2019-2025 | |
| Novo Nordisk INC | $372.18 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $275.32 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $189.85 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.85 | 2019-2025 | Jardiance |
| Amgen INC. | $127.10 | 2019-2025 | Repatha, Prolia, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.64 | 2019-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $94.08 | 2019-2023 | Eliquis |
| Abbott Laboratories | $88.02 | 2022-2024 | Freestyle Libre, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $81.54 | 2021-2024 | Xarelto |
| Exact Sciences Corporation | $78.38 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $65.95 | 2019 | |
| Abbvie INC. | $52.94 | 2023-2024 | |
| Vital Connect, INC | $51.21 | 2023 | Vitalpatch Rtm |
| Dexcom, INC. | $48.63 | 2025 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $47.91 | 2023-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $47.77 | 2019-2021 | |
| Allergan, INC. | $40.42 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $35.87 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $35.40 | 2019 | |
| Boston Scientific Corporation | $33.42 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Esperion Therapeutics, INC. | $33.16 | 2021-2022 | |
| Astellas Pharma US INC | $31.10 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $29.89 | 2022-2024 | |
| Philips North America LLC | $24.84 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Genentech USA, INC. | $18.91 | 2020 | |
| Scilex Pharmaceuticals INC. | $18.50 | 2019 | |
| Amarin Pharma, INC. | $18.12 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.67 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.16 | 2024 | Ajovy |
| Aytu Biopharma, INC. | $13.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.13 | 2020 | |
| Merck Sharp & Dohme LLC | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fayssoux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.